Bluenote develops a generative AI platform specifically for the life sciences industry. The system automates complex regulatory workflows to help pharmaceutical, medical device, and diagnostics companies accelerate their submissions to regulatory bodies. The platform's core function is to generate first drafts of critical documentation across more than 15 application areas, including regulatory filings, technical reports, protocols, SOPs, and manufacturing documentation.
The technology focuses on fine-tuning AI models for this specialized domain. According to the company, its fine-tuned models are preferred over off-the-shelf alternatives by 90% of users in testing. This specialization is designed to produce documents that meet the stringent requirements of regulatory environments, spanning the entire product lifecycle from preclinical stages through commercial phases.
The platform is built to address a significant bottleneck in the life sciences pipeline. By automating the drafting of routine regulatory and technical documents, Bluenote aims to compress timelines for bringing new products to market. The company reports that this approach can lead to regulatory submissions that are 50-75% faster compared to traditional methods.
